Quintrio
Home

BEVERAGES

SRX Global Inc

SRXH

SRX Global Inc is an AI-driven platform focused on investing in operating companies, strategic assets, and technology-enabled opportunities across multiple sectors. It uses technology and data analytics to identify and manage investments.

Last trade $0.8834
Day change -$0.0481 (-5.16%)
Day range $0.876 – $0.957
Volume 256,917
Market cap $19M

Open XASE

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$18.85M
Price / earnings
—
Price / book
0.13×
Price / sales
1.96×
EV / sales
-1.7×
EV / EBITDA
1.39×

Profitability

Earnings per share
-$0.94
Return on assets
-13.16%
Return on equity
-13.38%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
27.55×
Quick ratio
26.45×
Cash ratio
14.86×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$2.9M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for SRXH, quarterly periods
Line itemQ3 FY2026 Jun 30, 2026Q2 FY2026 Mar 31, 2026Q1 FY2026 Dec 31, 2025Q4 FY2025 Sep 30, 2025Q3 FY2025 Jun 30, 2025
Revenue$3.39M$3.44M$2.81M—$2.67M
Cost of revenue$2.49M$2.16M$1.75M$0$2.64M
Gross profit$904K$1.28M$1.05M—$31K
Selling, general and administrative$4.11M$3.09M$4.84M—$8.64M
Research and development$0$0$0—$0
Total operating expenses$4.11M$3.09M$4.84M—$8.64M
Operating income-$3.2M-$1.82M-$3.79M—-$8.61M
Interest expense-$569K-$1.78M-$1.29M—$30K
Income before taxes-$4.14M-$6.38M-$8.61M—-$6.85M
Income taxes$0$2K$4K—$0
Net income-$4.14M-$6.38M-$8.61M—-$15.13M
Net income attributable to common shareholders-$4.14M-$6.38M-$8.61M—-$15.13M
EBITDA-$3.19M-$1.89M-$3.78M-$2.89M-$10.11M
Basic earnings per share-$0.36-$1.20-$15.60—-$44.51
Diluted earnings per share-$0.36-$1.20-$15.60—-$44.51

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

SRX Global and CERO 1236, a Wholly-Owned SPV, Enter into Definitive Agreement to Acquire CERo Therapeutics, an Innovative Cellular Immunotherapy Company Developing CER 1236 for Hematologic Malignancies

SRX Global Inc. announced a definitive agreement to acquire CERo Therapeutics Holdings, Inc., an innovative cellular immunotherapy company developing CER-1236 for hematologic malignancies. The acquisition will be structured through a wholly-owned SPV (CERO 1236) to avoid diluting existing SRX shareholders. The transaction is expected to accelerate CER-1236's clinical development and provide CERo with enhanced access to capital and operational resources. CERo has treated six patients in its Phase 1 CERTAIN-T trial with no dose-limiting toxicities observed at increased dose levels.

Benzinga

SRx Health Solutions Closes EMJX Acquisition and Launches AI-Driven Platform Strategy Under New Name and Brand, SRX Global, Focused on Investments in High-Conviction Operating Companies and Assets

SRx Health Solutions has completed its acquisition of EMJ Crypto Technologies (EMJX) and rebranded as SRX Global Inc. The company is launching an AI-driven platform strategy focused on capital allocation into high-conviction operating companies and assets. The merged entity will be led by Kent Cunningham as CEO and Eric Jackson as President and Head of Asset Management, with initial investments in companies including Astro Capital, Opendoor Technologies, Uber Technologies, and Optimi Health Corp.

Benzinga

SRx Health Solutions Acquires 4.99% of Smartkem, Inc. (NASDAQ: SMTK)

SRx Health Solutions (NYSE: SRXH) has acquired a 4.99% stake in Smartkem, Inc. (NASDAQ: SMTK), a leader in advanced materials, through a shelf take down. The company also purchased convertible preferred securities in a non-brokered private placement. This acquisition comes as SRx Health Solutions is in the process of merging with EMJ Crypto Technologies (EMJX).

Benzinga

SRx Health Solutions Announces Board Approval to Dividend 75% of Profits from Investment in Astro Investment XVII, an Affiliate of Astro Capital and SPV with Investments in SpaceX and Other Artificial Intelligence and Space Companies

SRx Health Solutions' board approved a plan to dividend 75% of profits from its investment in Astro Investment XVII, a special purpose vehicle with stakes in SpaceX and AI/space companies. The company, which is merging with EMJ Crypto Technologies, invested over 10% of its investable capital in the SPV and will return capital to shareholders upon wind down.

Benzinga

SRx Health Solutions Acquires Shares of Compass Inc. and Increases Investment in Opendoor Technologies Inc.

SRx Health Solutions (SRXH) announced the acquisition of shares in Compass Inc. and increased its investment in Opendoor Technologies Inc. The company also filed a Form S-4 with the SEC regarding its proposed merger with EMJ Crypto Technologies (EMJX). SRXH reported approximately 3.5% gains in its hedging pool and 8% gains in long treasury investments through mid-April.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
Jul 22, 2026$0.05Aug 3, 2026special

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jul 6, 20261-for-60reverse split